|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
������͡ |
|
RXR |
|
Ƥ������ |
| ��������������� | |
|
���� |
|
������ |
| PubMed | |
|
Article by |
|
Article by |
������͡������Ƥ���Ƶ�Ӧ��
����, ������
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ�210042
������͡��һ�ֺϳɵ�άA��X���弤����,��άA��X����߶������Խ��,��Ҫͨ��Ӱ����άA��X�����γ��������Ķ���ϸ�������巢�ӵ���ϸ����������ֳ��ֻ������á�������,����ϵͳ�;ֲ�Ӧ����Ӧ֤�IJ�������,�����û��Ƶ��о�Ҳ�������롣
[2] Solomon C, White JH, Kremer R. Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor alpha. J Clin Invest,1999, 103:1729-1735.
[3] Zhang C, Duvic M. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther, 2003,16:322-330.
[4] Song JI, Lango MN, Hwang JD, et al. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid ( LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res, 2001,61:5919-5925.
[5] Mukherjee R, Strasser J, Jow L,et al. RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioscler Thromb Vasc Biol, 1998, 18:272-276.
[6] Agarwal VR, Bischoff ED, Hermann T, et al. Induction of adipocytespecific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin). Cancer Res,2000, 60:6033-6038.
[7] Li D, Li T, Wang F, et al. Functional evidence for retinoid X receptor (RXR) as a nonsilent partner in the thyroid hormone receptor/RXR heterodimer. Mol Cell Biol, 2002, 22:5782-5792.
[8] Liu S, Ogilvie KM, Klausing K, et al. Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat. Endocrinology, 2002, 143:2880-2885.
[9] Zhao Y, Qin S, Atangan LI, et al. Casein kinase 1alpha interacts with retinoid X receptor and interferes with agonist-induced apoptosis.J Biol Chem, 2004, 279:30844-30849.
[10] Lowe MN, Plosker GL. Bexarotene. Am J Clin Dermatol, 2000, 1:245-250.
[11] Howell SR, Shirley MA, Grese TA, et al. Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors. Drug Metab Dispos, 2001, 29:990.
[12] Querfeld C, Rosen ST, Guitart J, et al. Comparison of selective retinoic acid receptor-and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma. J Am Acad Dermatol, 2004, 51:25-32.
[13] Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase �� clinical trial. J Am Acad Dermatol, 2003,49:801-815.
[14] Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol, 2002,47:672-684.
[15] McGinnis KS, Shapiro M, Vittorio CC, et al. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous Tcell lymphoma. Arch Dermatol, 2003, 139:771-775.
[16] Shapiro M, Rook AH, Lehrer MS, et al. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage ��a cutaneous T-cell lymphoma. J Am Acad Dermatol, 2002, 47:956-961.
[17] McGinnis KS, Junkins-Hopkins JM, Crawford G, et al. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol, 2004, 50:375.
[18] Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood, 2002, 100:1399-1403.
[19] Smit JV, de Jong EM, van Hooijdonk CA, et al. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J Am Acad Dermatol, 2004, 51:257-264.
[20] Franssen ME, Smit JV, Van Erp PE, et al. A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion. Br J Dermatol, 2003, 149:506-512.
[21] Hanifin JM, Stevens V, Sheth P, et al. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol, 2004, 150:545-553.
[22] Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med,1999, 340:1075-1079.